Skip to search formSkip to main contentSkip to account menu

cetuximab

Known as: Cetuximab [Chemical/Ingredient], Anti-EGFR Monoclonal Antibody, Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 
A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
BACKGROUND We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line… 
Highly Cited
2009
Highly Cited
2009
BACKGROUND Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is… 
Highly Cited
2008
Highly Cited
2008
BACKGROUND Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We… 
Highly Cited
2008
Highly Cited
2008
BACKGROUND Treatment with cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, improves… 
Highly Cited
2008
Highly Cited
2008
PURPOSE Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS… 
Highly Cited
2007
Highly Cited
2007
BACKGROUND Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a… 
Highly Cited
2006
Highly Cited
2006
The anti-epidermal growth factor receptor (anti-EGFR) cetuximab has been proven to be efficient in metastatic colorectal cancer… 
Highly Cited
2004
Highly Cited
2004
BACKGROUND The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer… 
Highly Cited
2004
Highly Cited
2004
PURPOSE To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory…